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Abstract
Background: Periodontitis has been regarded as a potential risk factor for rheumatoid arthritis (RA). A systematic 
review is made to determine whether nonsurgical periodontal treatment in patients with RA offers benefits in 
terms of the clinical activity and inflammatory markers of the disease.
Material and Methods: A search was made of the Medline-PubMed, Cochrane, Embase and Scopus databases to 
identify studies on the relationship between the two disease processes, and especially on the effects of nonsurgical 
treatment in patients of this kind. The search was based on the following keywords: rheumatoid arthritis AND 
periodontitis (MeSH), rheumatoid arthritis AND periodontal treatment.
Results: Eight articles on the nonsurgical treatment of patients with periodontitis and RA were finally included 
in the study. All of them evaluated clinical (DAS28) and laboratory test activity (ESR, CRP, IL-6, TNFα) before 
and after treatment. A clear decrease in DAS28 score and ESR was recorded, while other parameters such as CRP, 
IL-6 and TNFα showed a nonsignificant tendency to decrease as a result of treatment.
Conclusions: Nonsurgical treatment improved the periodontal condition of patients with periodontitis and RA, 
with beneficial effects upon the clinical and laboratory test parameters (DAS28 and ESR), while other inflam-
matory markers showed a marked tendency to decrease. However, all the studies included in the review involved 
small samples sizes and follow-up periods of no more than 6 months. Larger and particularly longitudinal studies 
are therefore needed to more firmly establish possible significant relations between the two disease processes.
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Introduction
Periodontal disease (PD) is one of the most frequent oral 
disorders, particularly in elderly patients, and is one of 
the most common causes of tooth loss. Periodontitis 
causes chronic inflammation, with the constant release 
of inflammatory mediators, and may be a risk factor for 
the development of other systemic inflammatory disor-
ders (1).
There is now considerable evidence supporting the as-
sociation between periodontitis and certain chronic in-
flammatory processes such as cardiovascular disease, 
diabetes mellitus, obesity and certain alterations during 
pregnancy. In recent years rheumatoid arthritis (RA) 
has also been included among these potentially associ-
ated disorders (2).
Rheumatoid arthritis is an autoimmune disease char-
acterized by chronic inflammation of the joints, par-
ticularly the small joints of the hands and feet, with 
progressive destruction resulting in variable degrees of 
deformity and functional disability. Inflammation plays 
a key role in the origin of RA, its chronification, and 
in progression of the disease with soft and hard tissue 
destruction, in a way similar to the situation seen in pa-
tients with chronic periodontitis (3).
Most of the mentioned associations can be explained in 
part by an excessive secretion of cytokines and other 
inflammatory mediators produced in response to an 
altered host immune reaction. There appears to be an 
imbalance between proinflammatory and antiinflam-
matory mediators that would be the cause of the tissue 
damage. Certain cytokines are ultimately correlated to 
such damage, such as interleukin 1 (IL-1), tumor necro-
sis factor-α (TNFα) and prostaglandin E2 (4-6).
A number of hypotheses have tried to explain the rela-
tionship between PD and RA. The currently most widely 
accepted hypothesis is the “double hit model”, which 
postulates that a first “hit” in the form of inflammation 
due to periodontitis is followed by a second “hit” at joint 
level, with an exacerbation of the inflammatory response 
in these locations. Another hypothesis points to the de-
velopment of an autoimmune response generated by 
proteins partially altered by enzymes of bacterial origin, 
such as anti-citrullinated protein antibodies in RA (7-9).
A number of laboratory test parameters (acute phase 
reactants) may experience clear alterations during the 
active phases of RA, such as C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), rheumatoid fac-
tor (RF), interleukin 1β (IL-1β), interleukin 6 (IL-6) or 
TNFα (5,10).
With regard to this possible bidirectional relationship 
between PD and RA, changes have been described in 
the aforementioned biochemical markers after nonsur-
gical periodontal treatment, implying a decrease in the 
inflammation generated at periodontal level, and this in 
turn could exert a positive influence upon RA.
The aim of this study was to conduct a systematic re-
view of the literature supported by a certain level of evi-
dence, in an attempt to determine whether nonsurgical 
periodontal treatment in patients with RA offers ben-
efits in terms of the clinical activity and inflammatory 
markers of the disease.
Material and Methods
- Search strategy
Two search steps were established in the present review. 
In a first step we conducted a search of the Medline-
PubMed database to retrieve articles that had studied 
the possible relationship between PD and RA, focus-
ing particularly on the effect of nonsurgical periodontal 
treatment in patients with arthritis and periodontitis. 
The search covered the period up to February 2015, and 
was limited to articles published in English.
The following descriptors were used: rheumatoid ar-
thritis AND periodontitis (MeSH), resulting in a total 
of 362 references which were then analyzed on the basis 
of the title of the article or the abstract, and the index 
terms included in the publication. The following inclu-
sion criteria were applied:
1) Controlled clinical studies on the effect (intervention) 
of nonsurgical periodontal treatment in patients with 
RA and periodontitis. 
2) Patients diagnosed with RA and periodontitis and 
aged over 30 years.
3) The absence of systemic inflammatory diseases capa-
ble of influencing RA or periodontitis.
4) The absence of antibacterial drug use in the three 
months before periodontal treatment.
5) The absence of periodontal treatment at least during 
the previous 6 months.
6) The presence of an age- and gender-matched control 
group without periodontal treatment.
7) Articles published in English.
In a second step we conducted a search in the Medline-
PubMed, Cochrane, Embase and Scopus databases, 
using the following terms: rheumatoid arthritis AND 
periodontal treatment. A total of 191 articles were iden-
tified. After screening both searches according to the 
established inclusion criteria, and after eliminating du-
plicate studies, a total of 8 articles were obtained (Table 
1): 7 controlled studies (11-17) and one clinical trial (18). 
In addition, 31 reviews were retrieved, though only 
one systematic review and metaanalysis of periodontal 
treatment in RA was identified (19).
Results
The 8 studies finally included in the analysis focused on 
the nonsurgical periodontal treatment of patients with 
RA and periodontitis. Periodontal treatment included 
instructions referred to oral hygiene, supragingival 
(16) and subgingival cleaning with ultrasound, and root 
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rasping and scaling (11-15,17,18). One study adminis-
tered antibiotic treatment and an antiseptic rinse (18), 
while the study published by Ranade et al. (15) moreo-
ver included occlusal adjustment.
The study parameters were assessed at baseline before 
the intervention and over a follow-up period of 6 weeks 
(13), 8 weeks (12,16), three months (11,18) and 6 months 
(14,17). The study of Ranade et al. (15) only specified 
that evaluation was made weeks after periodontal treat-
ment.
In general, all the studies evaluated the changes in the 
activity of the disease (RA) associated to treatment of 
the periodontal infection and inflammation, based on 
the measurement of different clinical and laboratory 
test parameters. The inclusion criteria also controlled 
comorbidities with a view to ensuring that there were 
no other concomitant inflammatory conditions capa-
ble of altering the results. In addition to examining the 
effect of the intervention, Pinho et al. (14) established 
comparisons according to RA treatment with antirheu-
matic agents or disease-modifying antirheumatic drugs 
(TNFα inhibitors). The sample size referred to the pa-
tients with RA subjected to periodontal treatment var-
ied from 10 (15) to 75 (14).
In 7 studies the evaluation of disease activity was based 
on the Health Assessment Questionnaire (HAQ) (11,15) 
and the Disease Activity Score in 28 joints (DAS28). In 
some cases CRP was measured as acute phase reactant, 
while others studies recorded ESR. The DAS28 score 
tended to decrease after nonsurgical periodontal treat-
ment. Seven studies (85.7%) evidenced clear clinical 
improvement of RA after treatment (11-13,15-18), and 
in one case improvement of the periodontal parameters 
was greater in the RA group than among the non-RA 
controls. 
Both ESR and CRP are systemic inflammatory markers 
that can be used to determine the degree of activity of 
the disease (RA) at a given point in time. In this regard, 
a clear decrease in ESR was observed following peri-
odontal treatment (11-14), though the decrease in CRP 
failed to reach statistical significance. Likewise, other 
proinflammatory cytokines such as TNFα and IL-6 also 
tended to decrease, though not to a significant extent 
(19).
 
Ribeiro, et al. 
2005 (11) 
n1=16 supra-gingival scaling 
n2=16 !PT sub-gingival 
(51.6y) (88.5%F) 
F= 3 months Decreased ESR 
Al-Katma, et al. 
2007 (12) 
n=17 RA+PT 
(55.0y)(88.0%F) 
nc=12 RA without PT 
(51.7y) (83.0%F) 
F= 8 weeks Decreased severity RA 
Ortiz, et al. 
2009 (13) 
nA=20 RA +PT 
(69y)(80%F) 
nB=20 RA without PT 
(49y) (100%F) 
F= 8 weeks Symptoms and signs 
improvement 
Pinho, et al. 
2009 (14) 
n=75 en 5 groups of 15. RA 
with and without 
PT,RA+prothesis+PT, PT no 
AR, Control no PD no AR 
(50y) (60%F) 
F=6 months Unclear results 
Ranade, Doiphode  
2012 (15) 
RA n=40 
No RA=40 
PT in 10 
F= weeks after Decreased periodontal 
parameters 
Okada, et al. 
2013 (16) 
n= 15 RA PT 
(60.7y) (84.6%F) 
nc= 29 RA without PT 
(62.7y) (82.8%F) 
F=8 weeks Decreased DAS28, 
serum levels of IgG to 
Porphyromona 
gingivalis and citrulline. 
Biyikoglu, et al. 
2013 (17)  
n=15 AR with PD 
nc=15 PD no RA 
F= 1, 3 y 6 months  improvement RA 
Monsarrat, et al.  
2013 (18) 
40 patiets RA in:  
ni=20 RA+PT 
nc=20 RA without PT 
F= 3 months mild clinical 
improvement and 
stabilizes RA 
Table 1. Sample characteristics, monitoring and conclusions of the 8 studies included.
PT: periodontal treatment, y: years, F: female, F: Follow-up, ESR: erithrocyte sedimentation rate, DAS 28: disease activ-
ity score 28, RA=rheumatoid arthritis.
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Rheumatoid factor (RF) has been used for years as a 
marker for assessing RA, though it lacks specificity. In 
fact, 15% of all arthritic patients may prove seronega-
tive for RF. None of the studies evaluated by Kaur et al. 
(19) demonstrated changes in RF following nonsurgical 
periodontal treatment.
Anti-citrullinated protein antibodies (ACPAs) are a 
result of inflammation, and their presence in serum is 
quite specific of RA (95%). These antibodies were eval-
uated in the study published by Okada (16), though no 
significant differences were found.
Discussion
- Common physiopathological mechanisms
Both rheumatoid arthritis (RA) and periodontal disease 
(PD) may share common physiopathological mecha-
nisms characterized by chronic inflammation in which 
the end result is bone reabsorption of the supporting 
structures or alterations of the small body joints (2). 
These disorders involve a certain immune susceptibil-
ity combined with persistent inflammation which in the 
case of periodontal disease (PD) is produced by subgin-
gival bacterial plaque. The periodontal inflammatory 
state maintains synergic interaction with the plaque to 
increase its protection against the host defense mecha-
nisms, acquire nutrients, and create an environment 
favorable to perpetuation of the bacterial plaque. This 
situation gives rise to a feedback mechanism between 
the plaque and the tissue inflammation known as “in-
flammophilia” (20,21).
Rheumatoid arthritis is characterized by different stim-
uli that can induce an arthrogenic inflammatory reac-
tion with the influence of endogenous products such 
as certain connective tissue proteins or even altered 
immunoglobulins. Certain bacteria capable of causing 
periodontal disease, such as Porphyromona gingivalis 
(Pg), are able to produce the citrullination of host pro-
teins, mediated by peptidyl arginine deiminase (PAD), 
transforming them into antigens (22).
- Citrullination
Until some time ago, the only marker for monitoring 
RA was the laboratory test determination of rheumatoid 
factor (RF), an antibody targeted to the constant frac-
tion (Fc) of IgG. In fact, RF assessment is regarded as 
a diagnostic criterion for RA. However, RF is neither 
sensitive nor specific, since it can also be found in other 
autoimmune disorders, in oncological diseases, chronic 
infections, and even in normal elderly people (23).
At present, other antibodies have been associated to ar-
thritis, such as antifilaggrin or antiprofilaggrin antibod-
ies, which act against the antiperinuclear factor (APF). 
Filaggrin is an epidermal protein that establishes bonds 
between the keratin intermediate filaments during the 
terminal stages of epithelial cell differentiation, while 
profilaggrin is the precursor composed of 10-12 filag-
grin molecules (24). Mention also must be made of an-
tikeratin antibodies (AKAs) and anti-Sa antibodies in 
which citrulline is implicated as antigenic determinant, 
and vimentin. The latter is a fibrous protein that forms 
intermediate filaments of the cytoskeleton, and is wide-
ly expressed in embryonic, endothelial and blood cells. 
As a proinflammatory agent, tumor necrosis factor-α 
can induce the secretion of vimentin, while interleukin 
10 (IL-10), as an inhibitory cytokine, blocks vimentin 
(25).
Other intervening antibodies are anti-citrullinated cy-
clic peptide antibodies (ACCPs), which are very sensi-
tive (80%) and specific (98%) of RA. These antibodies 
moreover manifest in very early stages of the disease 
(26).
In general, the proteins implicated as antigenic stimuli 
in the pathogenesis of RA have suffered post-transla-
tion changes following their synthesis – one of the most 
common modifications being citrullination. The latter 
involves the conversion of an arginine group into a cit-
rulline group, catalyzed by peptidyl arginine deiminase 
(PAD) in the presence of calcium. The result is a change in 
molecular weight and a loss of positive electrical charge, 
modifying the capacity of the molecule to interact with 
other proteins and making it more vulnerable to proteo-
lytic degradation mediated by other enzymes (27).
Five PAD isotypes have been identified, each with a 
specific tissue expression profile. In this regard, PAD 1 
is mainly expressed by the epidermis and uterus; PAD 
2 is expressed by skeletal muscle, the spleen, brain and 
salivary glands among other tissues; PAD 3 is expressed 
by hair follicles; PAD 4 is expressed by neutrophils and 
eosinophils; and PAD 5 has been detected in ovaries, 
testicles and peripheral blood leukocytes (28).
The activity of PAD appears to be influenced by a range 
of estrogenic compounds. It also must be taken into ac-
count that during apoptosis, some cell proteins are cit-
rullinated – particularly vimentin. In this respect, cit-
rullination can induce almost complete depolymeriza-
tion, resulting in alteration of the cytoskeletal network 
(29).
However, PAD 2 and PAD 4 are the only isotypes acting 
upon proteins such as fibrin and vimentin in the syno-
vial tissue of patients with arthritis, and can generate 
an immune response by converting into antigenic ele-
ments. Specifically, PAD 4 reportedly may react in the 
serum of patients with RA, thereby intrinsically acting 
as a neoantigen (30).
The immune response may be mediated by B cells, am-
plifying in susceptible individuals and generating plas-
ma cells with the secretion of antibodies. Likewise, T 
lymphocytes may act against the citrullinated proteins 
of the synovial membrane, which constitutes the target 
organ of the immune response.
Clinical studies of early arthritis have identified highly 
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specific antibodies targeted to citrullinated peptides and 
which might serve as diagnostic markers of the disease. 
The fibrin alpha- and beta-chains are relevant citrulli-
nated proteins in inflammatory synovial tissue, and the 
antibodies targeted to these molecules have greater spe-
cificity for RA (31,32).
Although the diagnosis of RA is presently fundamented 
upon patient anamnesis and physical examination, and 
on the findings of the radiological studies, the evalua-
tion of antibodies against citrullinated proteins may be 
of great help, particularly in patients with negative RF 
titers, and when the disease presents a poorer diagnosis 
(27).
- Periodontal treatment and disease activity
Regarding the possible relationship between periodon-
tal treatment and disease activity, it has been suggested 
that the control of periodontal disease could contrib-
ute to lessen infection and periodontal inflammation 
through the adoption preventive measures with good 
oral hygiene, supragingival and subgingival cleaning 
with ultrasound, and root rasping and scaling. These 
measures could reduce the clinical activity of RA, with 
a decrease in the serum levels of certain products de-
rived from the inflammatory process (13).
Our systematic review indicates that the application of 
conservative treatments clearly improves the periodon-
tal parameters (bleeding upon probing, pocket depth 
and attachment loss) in patients with RA and chronic 
periodontal disease (15). Furthermore, this periodontal 
improvement was seen to be associated to beneficial ef-
fects in relation to other disease assessment parameters 
such as the DAS28 score (12,13,16) and ESR (11-14). In 
this regard, ESR decreased significantly – suggesting a 
reduction in systemic inflammation following nonsur-
gical periodontal treatment.
The DAS28 score showed a tendency towards lessened 
signs and symptoms of disease, with a decrease in the 
number of painful joints, and lesser morning stiffness 
and joint effusion, independently of the drugs used to 
treat RA. Although Pinho et al. (14) found the differ-
ences between the studied groups to be significant at 
three months of follow-up, significance was lost after 
6 months. The follow-up periods in the different stud-
ies ranged from 6 weeks to 6 months, and might be too 
short to detect clinical changes referred to periodontal 
infection and inflammation.
Regarding other analyzed laboratory factors, RF was 
evaluated in three studies, while IL-6 and anti-citrulli-
nated cyclic peptide antibodies (ACCPs) were studied in 
another. However, other authors have shown that perio-
dontal treatment clearly reduces the CRP concentrations 
in patients without RA. Few of the studies included in 
the review analyzed the most important inflammatory 
parameters; the sample sizes were small; and the fact 
that the patients were receiving different drugs for ar-
thritis (antiinflammatory drugs and disease-modifying 
antirheumatic drugs) may have been a confounding 
factor. Furthermore, in many cases the randomization 
method used was not clear.
While the existing level of evidence is low, it seems 
clear that a decrease in periodontal inflammation in 
some way influences the level of systemic inflamma-
tion, and appears to contribute to clinical improvement 
of the disease.
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